Format

Send to

Choose Destination
Sci Rep. 2019 Sep 9;9(1):12901. doi: 10.1038/s41598-019-49579-y.

A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector.

Author information

1
Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Japan.
2
Research Center for Development of Recombinant VLP Vaccines, Research Institutes of Excellence, Mie University, Tsu, Japan.
3
BioComo Inc., Komono, Mie, Japan.
4
Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Japan. m-fukumura@biocomo.jp.
5
Research Center for Development of Recombinant VLP Vaccines, Research Institutes of Excellence, Mie University, Tsu, Japan. m-fukumura@biocomo.jp.
6
BioComo Inc., Komono, Mie, Japan. m-fukumura@biocomo.jp.
7
Division of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
8
Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
9
Department of Neural Regeneration and Cell Communication, Mie University Graduate School of Medicine, Tsu, Japan.
10
Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
11
Multi-Modal Microstructure Analysis Unit, RIKEN-JEOL Collaboration Center, Kobe, Japan.
12
Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University, Kasugai, Japan.
13
Department of Physiology, Mie University Graduate School of Medicine, Tsu, Japan.
14
Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Japan. nosaka@doc.medic.mie-u.ac.jp.
15
Research Center for Development of Recombinant VLP Vaccines, Research Institutes of Excellence, Mie University, Tsu, Japan. nosaka@doc.medic.mie-u.ac.jp.

Abstract

Ectopic protein with proper steric structure was efficiently loaded onto the envelope of the F gene-defective BC-PIV vector derived from human parainfluenza virus type 2 (hPIV2) by a reverse genetics method of recombinant virus production. Further, ectopic antigenic peptide was successfully loaded either outside, inside, or at both sides of the envelope of the vector. The BC-PIV vector harboring the Ebola virus GP gene was able to elicit neutralizing antibodies in mice. In addition, BC-PIV with antigenic epitopes of both melanoma gp100 and WT1 tumor antigen induced a CD8+ T-cell-mediated response in tumor-transplanted syngeneic mice. Considering the low pathogenicity and recurrent infections of parental hPIV2, BC-PIV can be used as a versatile vector with high safety for recombinant vaccine development, addressing unmet medical needs.

PMID:
31501502
PMCID:
PMC6733870
DOI:
10.1038/s41598-019-49579-y
Free full text

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center